Company
Bausch Health
Bausch Health has 49 drugs tracked on RxWires: 12 post-market, 12 approved, 12 in Phase 3, 9 in Phase 2, 4 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Polyethylene glycol | Post-Market | Colon Cleansing |
| Rifaximin 200 mg Tablet | Post-Market | Diarrhea |
| High dose budesonide rectal foam | Post-Market | Ulcerative Colitis |
| nabilone | Post-Market | Neuropathic Pain |
| Contrave 8Mg-90Mg Extended-Release Tablet | Post-Market | Obesity |
| Brodalumab | Post-Market | Psoriasis |
| Low Dose Budesonide | Post-Market | Ulcerative Colitis |
| bupropion hydrobromide | Post-Market | Major Depressive Disorder |
| IDP-122 Lotion | Post-Market | Psoriasis |
| IDP-118 Lotion | Post-Market | Psoriasis |
| Mesalamine (5-aminosalicylic acid, Apriso) | Post-Market | HIV Infections |
| CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%. | Post-Market | Acne Vulgaris |
| RENOVA | Approved | |
| DERMATOP E EMOLLIENT | Approved | |
| MINITRAN | Approved | |
| NORGESIC FORTE | Approved | |
| TETRABENAZINE | Approved | |
| ISTALOL | Approved | |
| POLYMYXIN B SULFATE AND TRIMETHOPRIM | Approved | |
| CHLORDIAZEPOXIDE HYDROCHLORIDE | Approved | |
| XIIDRA | Approved | |
| FLUOXYMESTERONE | Approved | |
| CETACORT | Approved | |
| TRISORALEN | Approved | |
| Blood sampling, endoscopy | Phase 3 | Ulcerative Colitis |
| Tramadol HCl ER | Phase 3 | Chronic Pain |
| IDP-126 Gel | Phase 3 | Acne Vulgaris |
| Encapsulated Mesalamine Granules (eMG) | Phase 3 | Ulcerative Colitis |
| Viramidine | Phase 3 | Chronic Hepatitis C |
| IDP-121 Lotion | Phase 3 | Acne |
| SC Methylnaltrexone (MNTX) | Phase 3 | Terminal Illness |
| 5 ASA, enemas, suppositories, corticosteroids | Phase 3 | Ulcerative Colitis |
| IDP-120 Gel | Phase 3 | Acne Vulgaris |
| Rifaximin SSD | Phase 3 | Hepatic Encephalopathy |
| Larsucosterol | Phase 3 | Hepatitis |
| Plecanatide | Phase 3 | Irritable Bowel Syndrome Characterized by Constipation |
| SC MNTX | Phase 2 | Bowel Dysfunction |
| Placebo Comparator | Phase 2 | Crohn's Disease |
| N-methylnaltrexone bromide (MOA-728) | Phase 2 | Constipation |
| 70 mg SC | Phase 2 | Psoriasis |
| lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination | Phase 2 | Actinic Keratosis |
| Metyrosine | Phase 2 | Velo-cardio-facial Syndrome |
| Flucytosine and fluconazole | Phase 2 | Cryptococcal Infection Disseminated |
| IDP-123 Lotion | Phase 2 | Acne Vulgaris |
| BL1107 | Phase 2 | Dry Eye Disease |
| Apriso 0.375G ER CAP | Phase 1 | Ulcerative Colitis |
| 50 mg/mL Virazole | Phase 1 | COVID19 |
| MOA-728 | Phase 1 | Adult |
| 700 mg IV | Phase 1 | Psoriasis |
Latest
- Idp 118 Lotion moved to Post-Market
- Idp 122 Lotion moved to Post-Market
- Idp 118 Lotion moved to Phase 3
- Label updated: TETRABENAZINE
- Label updated: TIMOLOL MALEATE
Follow Bausch Health on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.